Update: This article was updated to include a statement from the U.S. Patent and Trademark Office.

Erich Spangenberg, one of the principal architects of a campaign challenging the validity of more than 30 pharmaceutical patents at the U.S. Patent and Trademark Office, suggested on Monday that PTO Director Michelle Lee may have interfered with challenges brought by his campaign.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]